Friday, 19 October 2018

Natco Pharma releases Hepatitis C drug in India

03 July 2018 | News

The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets.

Image credit- npr.org

Image credit- npr.org

Fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, has been launched by Natco Pharma in India. 

The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets, used for the treatment of patients with chronic Hepatitis C virus (HCV) infection 

The company has launched the drug at a maximum retail price of Rs 17,500 for a bottle of 28 tablets. 

 
 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Click Here!




Survey Box

Can blockchain help cease fake drug distribution in India?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls